MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-20-2025
Summit Therapeutics P/S Ratio 2011-2025 | SMMT
Annual P/S Ratio Summit Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 406 | 200 | 485 | 3.45 | 22.3 | 275 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 485 | 3.45 | 232 |
P/S Ratio of other stocks in the Biotechnology industry
| Issuer | P/S Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AC Immune SA
ACIU
|
35 | $ 2.8 | 2.19 % | $ 229 M |  Schweiz |
 |
ADiTx Therapeutics
ADTX
|
0.442 | $ 2.49 | -11.39 % | $ 32.8 K |  USA |
 |
Aeterna Zentaris
AEZS
|
7.87 | - | 5.93 % | $ 314 M |  Canada |
 |
Abeona Therapeutics
ABEO
|
42.7 | $ 4.59 | -4.08 % | $ 98.1 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
65.5 | - | - | $ 26.5 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
0.654 | $ 12.12 | -1.58 % | $ 3.74 B | USA |
 |
Acer Therapeutics
ACER
|
25.8 | - | 2.71 % | $ 14 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
110 | $ 5.37 | -20.68 % | $ 194 M | USA |
 |
argenx SE
ARGX
|
311 | $ 919.62 | 2.76 % | $ 25 B |  Niderland |
 |
Ascendis Pharma A/S
ASND
|
947 | $ 203.0 | -3.72 % | $ 5 B |  Danmark |
 |
Achieve Life Sciences
ACHV
|
3.19 | $ 4.64 | -0.32 % | $ 92 M | USA |
 |
BioDelivery Sciences International
BDSI
|
1.85 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
66.4 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Acorda Therapeutics
ACOR
|
0.142 | - | -24.86 % | $ 820 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
131 | $ 3.36 | 2.73 % | $ 8.08 B |  Australia |
 |
Acasti Pharma
ACST
|
0.203 | - | 4.01 % | $ 150 M | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
4.6 | $ 54.27 | -1.38 % | $ 10.3 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
34 | - | -15.15 % | $ 60.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.53 | - | - | $ 40.3 B | USA |
 |
Baudax Bio
BXRX
|
0.614 | - | 0.59 % | $ 63 K | USA |
 |
AbbVie
ABBV
|
22.7 | $ 224.99 | -0.01 % | $ 398 B | USA |
 |
Cara Therapeutics
CARA
|
2.58 | - | -3.03 % | $ 260 M | USA |
 |
CymaBay Therapeutics
CBAY
|
110 | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
0.0564 | - | - | $ 3.74 B | USA |
 |
BioNTech SE
BNTX
|
35.7 | $ 96.22 | -1.21 % | $ 27.2 B |  Germany |
 |
Codiak BioSciences
CDAK
|
10.5 | - | -55.98 % | $ 2.15 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
6.58 | $ 18.75 | -0.48 % | $ 2.76 B | USA |
 |
Avid Bioservices
CDMO
|
3.03 | - | - | $ 789 M | USA |
 |
BioXcel Therapeutics
BTAI
|
2.37 | $ 1.92 | -7.01 % | $ 4.87 M | USA |
 |
Biogen
BIIB
|
2 | $ 179.76 | 1.11 % | $ 26.2 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.39 K | - | -1.52 % | $ 24.7 M | USA |
 |
Beam Therapeutics
BEAM
|
39.4 | $ 23.52 | -2.22 % | $ 1.94 B | USA |
 |
AbCellera Biologics
ABCL
|
29.8 | $ 3.45 | -0.72 % | $ 1.02 B | Canada |
 |
Cabaletta Bio
CABA
|
50.3 M | $ 2.37 | -2.67 % | $ 2.77 M | USA |
 |
Clearside Biomedical
CLSD
|
12.3 | - | - | $ 25.3 M | USA |
 |
Celsion Corporation
CLSN
|
26.1 | - | -6.63 % | $ 13.9 M | USA |
 |
Clovis Oncology
CLVS
|
1.55 | - | -7.23 % | $ 13 M | USA |
 |
Advaxis
ADXS
|
144 | - | -9.65 % | $ 45.9 M | USA |
 |
Chimerix
CMRX
|
320 | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
41.3 | - | - | $ 401 M | USA |